biostudies-literatureLasocki Sministère de la santéministère de la santé (FR)62https://www.ebi.ac.uk/biostudies/studies/S-EPMC7885380biostudies-literatureUnknown25(1)<h4>Background</h4>Anemia is a significant problem in patients on ICU. Its commonest cause, iron deficiency (ID), is difficult to diagnose in the context of inflammation. Hepcidin is a new marker of ID. We aimed to assess whether hepcidin levels would accurately guide treatment of ID in critically ill anemic patients after a prolonged ICU stay and affect the post-ICU outcomes.<h4>Methods</h4>In a controlled, single-blinded, multicenter study, anemic (WHO definition) critically ill patients with an ICU stay ≥ 5 days were randomized when discharge was expected to either intervention by hepcidin treatment protocol or control. In the intervention arm, patients were treated with intravenous iron (1 g of ferric carboxymaltose) when hepcidin was < 20 μg/l and with intravenous iron and erythropoieCritical care (London, England)Impact of treating iron deficiency, diagnosed according to hepcidin quantification, on outcomes after a prolonged ICU stay compared to standard care: a multicenter, randomized, single-blinded trial.PMC7885380STIC 2012 N° 2-12-0006Puy HGeneve CMercat AIsslame SLeger MAsfar PSeguin PHepcidane study groupNagot NLehmann SBarbaz MFerrandiere MChanques GKerforne TPeoc'h KGaillard TLefebvre TMontravers PLauney YAsehnoune KDelaby CBeloncle FRineau EMimoz OJaber SMercier GHirtz CSargentini CRoquilly ABoisson MMarin GGergaud SLasocki SDahyot-Fizelier CfalseImpact of treating iron deficiency, diagnosed according to hepcidin quantification, on outcomes after a prolonged ICU stay compared to standard care: a multicenter, randomized, single-blinded trial.<h4>Background</h4>Anemia is a significant problem in patients on ICU. Its commonest cause, iron deficiency (ID), is difficult to diagnose in the context of inflammation. Hepcidin is a new marker of ID. We aimed to assess whether hepcidin levels would accurately guide treatment of ID in critically ill anemic patients after a prolonged ICU stay and affect the post-ICU outcomes.<h4>Methods</h4>In a controlled, single-blinded, multicenter study, anemic (WHO definition) critically ill patients with an ICU stay ≥ 5 days were randomized when discharge was expected to either intervention by hepcidin treatment protocol or control. In the intervention arm, patients were treated with intravenous iron (1 g of ferric carboxymaltose) when hepcidin was < 20 μg/l and with intravenous iron and erythropoie2021-01-01T00:00:00Z2021 Feb2026-05-09T09:51:27.07Z2022-02-10T13:38:52.6ZS-EPMC78853803358889310.1186/s13054-020-03430-3